VOTING QUESTION #2 TO THE COMMITTEE October 6, 2022

2. For quadrivalent 2023 SH formulations of influenza vaccines, does the committee recommend:

A. Inclusion of a B/Phuket/3073/2013-like virus (B/Yamagata lineage) as the 2nd influenza B strain in the vaccine